|Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study; Medical Marijuana's HempMedsPX Participates in Conference|
|By Staff and Wire Reports|
|Thursday, 24 October 2013 19:10|
Myriad Genetics, Inc. (Nasdaq:MYGN) announced it will present data this week at the American Society of Human Genetics (ASHG) annual meeting in Boston showing that the Myriad myRisk Hereditary Cancer test meets rigorous quality standards and provides clinical sequencing results equivalent to 99.99 percent accuracy. Myriad myRisk Hereditary Cancer is a new diagnostic test that provides patients with information about their hereditary risk for eight major cancers including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma.
"Next-generation DNA sequencing offers the ability to test many genes at once, but it must be optimized to ensure clinical accuracy. We've invested three years of research to optimize our Myriad myRisk Hereditary Cancer test, and the validation data show that Myriad myRisk Hereditary Cancer offers 99.99 specificity and sensitivity which means it provides unprecedented quality and accuracy equal to the gold standard Sanger sequencing," said Richard J. Wenstrup, M.D., chief medical officer of Myriad. "As next-generation technology advances, mutation classification techniques also must evolve to ensure high quality data interpretation for clinical decision making. Myriad has developed a robust variant classification program called Myriad myVision™ to achieve highly accurate, clinically-actionable, genetic test results for patients and healthcare providers."
Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that HempMedsPX™—a corporate portfolio company of Medical Marijuana Inc. and the exclusive master distributor and contracted marketing company for CannaVest Corp. and Medical Marijuana, Inc.—is joining the discussion and exhibiting at the biennial International Drug Policy Reform Conference in Denver, Colorado from October 24-26.
HempMedsPX™ VP of Communications, Charles Vest, will discuss the rapidly growing demand for medical cannabis and the issues surrounding its limited availability. Over 1,000 attendees from around the world will be introduced to an alternative at the Drug Policy Alliance (DPA)-hosted conference: CBD-rich industrial hemp oil that is available in all fifty states and to more than forty countries.
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that provides physician-inspired solutions for patients with spinal disorders, today announced that it has entered into a three-year collaboration agreement with an experienced spine surgeon group to contribute to Alphatec Spine's product innovation as well as future development and commercialization of the Company's product pipeline.
Astro-Med, Inc. (NASDAQ: ALOT), a manufacturer of high tech specialty printers and consumables, is pleased to announce that Sidoti & Company, LLC initiated coverage on shares of Astro-Med in a research report. The firm set a BUY rating on ALOT stock.
athenahealth, Inc. (Nasdaq:ATHN), a leading provider of cloud-based practice management, electronic health record (EHR), and care coordination services, today announced the appointment of Amy Abernethy, MD, PhD to its Board of Directors. With this addition, athenahealth's board now comprises nine directors.
Athersys, Inc. (Nasdaq:ATHX) will release its third quarter 2013 financial results at approximately 4:00 PM (Eastern Time) on Thursday, November 14, 2013, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results.
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for the third quarter ended September 30, 2013.
Bovie Medical Corporation (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, is pleased to announce that the Company in conjunction with the American Urologic Gynecology Society (AUGS) and Warren Volker, MD presented J-Plasma® at the 34th annual AUGS Conference in Las Vegas last week.
Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez, M.D., to the position of Chief Medical Officer.
Cerner Corporation (Nasdaq:CERN) today announced results for the 2013 third quarter that ended September 28, 2013, delivering strong levels of bookings and earnings performance.
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the third quarter of 2013, after the close of the market on Thursday, November 7, 2013.
Digirad Corporation (Nasdaq:DRAD) announced today that the Delaware Chancery court has validated the May 3, 2013 election of its Board of Directors.
DR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that it will report financial results for the third quarter ended September 30, 2013 after the market close on Wednesday, November 6, 2013.
eHealth, Inc. (NASDAQ: EHTH), America's first and largest private health insurance exchange, announced today its financial results for the third quarter ended September 30, 2013.
FEI (Nasdaq:FEIC) today announced that it has completed the installation of a Tecnai Arctica™ cryo transmission electron microscope (cryo-TEM) at Nanyang Technological University (NTU) in Singapore.
IPC The Hospitalist Company, Inc. (Nasdaq:IPCM), a leading national hospitalist physician group practice, today announced financial results for the third quarter ended September 30, 2013.
IPC The Hospitalist Company, Inc. (Nasdaq:IPCM), a leading national hospitalist physician practice company, announced today that it has signed definitive agreements to acquire the assets of four affiliated entities: Park Avenue Health Care Management, LLC; Park Avenue Medical Associates, PC; Park Avenue Medical Associates, LLC; and Geriatric Services, PC (collectively, "Park Avenue").
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2013 on Wednesday, October 30 at 2013 after the markets close.
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey for the second year in a row.
Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2013 financial results on Thursday, November 7, 2013.
The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the three and nine months ended September 30, 2013.
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that data demonstrating its ongoing lipid nanoparticle (LNP) technology innovations, including the enablement of messenger RNA (mRNA), were presented at the 1st International mRNA Health Conference taking place in Tubingen, Germany from October 23-24, 2013 by Tekmira's Chief Scientific Officer, Dr. Ian MacLachlan.
TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2013 financial results on Thursday, November 7, 2013, after the close of the U.S. financial markets.
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and nine months ended September 30, 2013, before the opening of trading on Thursday, October 31, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, October 31.
Vical Incorporated (Nasdaq:VICL) today announced that a review of the company's progress toward clinical testing of its Vaxfectin®-formulated therapeutic vaccine against herpes simplex virus type 2 (HSV-2) will be presented at the 2nd International Conference and Exhibition on Cell & Gene Therapy, held in Orlando, Florida.
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of its previously announced public offering of 14,300,000 shares of its common stock at a public offering price of $3.50 per share.
Z Trim Holdings, Inc. (OTC Markets: ZTHO), a biotechnology company providing value-added ingredients to a variety of industries, will be featured at Global Food Forum, Inc.'s 2013 Clean Label Conference from October 29-30 at the Hyatt Lodge in Oak Brook, Illinois.